Chordate Presents Interim Report with Q&A

On Thursday, August 31st, Chordate Medical will release its interim report for Q2 2023. On the same day at 2 PM, the company will hold a webcast presentation and Q&A session with CEO Anders Weilandt and Västra Hamnen Corporate Finance. The presentation will be conducted in Swedish and can be followed via computer or mobile devices.

To register for the web conference, please sign up using the following link:

The number of spots is limited, so we recommend registering well in advance to secure your spot.

A recording of the web conference will be available on the company’s website and on the Västra Hamnen Corporate Finance YouTube channel after the conference concludes.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy